Proč a jak psát kazuistiku?

Vladimír Mihál

Onkologie 2020: 14(Suppl.B): 28-29 | DOI: 10.36290/xon.2020.031  

Isolated axial lymphadenopathy as the first symptom of squamous cell carcinoma of the vulva

Jana Mergancová, Jindřiška Mergancová, Kamila Černotová, Edita Šnáblová, Mária Hácová, Aleš Hlávka, Prokop Homola

Onkologie 2020: 14(Suppl.B): 30-33 | DOI: 10.36290/xon.2020.032  

The most common causes of malignant axillary lymphadenopathy include secondary impairment of the breast cancer, malignant melanoma and haemato-oncological disease. Descriptions of axial metastases with primary tumours of the lungs, gastrointestinal tract, ovaria and/or testicle or hypopharynx are rarely found in medical literature. To determine a differential diagnosis, we focus mainly on results from histological examinations and from other examinations such as mammological, dermatological, endoscopic, pulmonary or ENT. Multi-disciplinary commissions usually come out with such diagnoses very often. We present in our paper the case history of an 86-year-old...

Nivolumab-induced hepatitis in a patient treated for malignant melanoma

Jan Šustr, Ondřej Fiala, Samuel Vokurka, Jindřich Fínek, Jana Kulhánková, Karel Balihar, Lukáš Kielberger

Onkologie 2020: 14(Suppl.B): 34-36 | DOI: 10.36290/xon.2020.033  

Nivolumab is still relatively new modality of treatment that we use nowadays to treat many malignant diseases such as renal carcinoma, urotelial carcinoma, lung carcinoma as well as malignant melanoma. Despite its excellent treatment results it comes with a number of side effects such as skin rash, colitis, pneumonitis or hepatitis. Most of its side effects are well manageable and do not require permanent cessation of treatment. In this described case report we see relatively rare case of severe hepatopathy which did not respond to conventional immunosuppressive therapy and led to permanent cessation of nivolumab treatment. Diagnostic procedures, therapeutic...

Case report of the meaning therapeutical response of the NSCLC after pembrolizumab monotherapy

Jaromír Roubec

Onkologie 2020: 14(Suppl.B): 37-39 | DOI: 10.36290/xon.2020.034  

The authors present a case report of a successful treatment by pembrolizumab in an elderly man with with adenocarcioma of lung. The aim is to show the case of the successfull anticancer therapy in elderly patient, the today standard therapy by immunotherapy outside of clinical trials in the Czech republic.

When not even four ALK inhibitors are enough

Martin Svatoň, Jan Baxa, Petr Mukenšnabl, Tomáš Vaněček, Miloš Pešek

Onkologie 2020: 14(Suppl.B): 40-43 | DOI: 10.36290/xon.2020.035  

Our case report describes a non-smoker with generalized pulmonary adenocarcinoma with ALK translocation. After the first two lines of chemotherapy, access to crizotinib was obtained. However, very soon, a second, small-sized lesion has developed, described as a metastasis in the contralateral lung. Subsequent use of higher generation ALK inhibitors (ceritinib, alectinib, lorlatinib) did not prevent progression in the right lung. It was shown later that the cause of this progression is not metastatic spread of adenocarcinoma in the right lung, but transformation to squamous lung carcinoma with ALK translocation. With this article, we would like to draw...

Patient with metastatic malignant melanoma treated with pembrolizumab

Alena Fialová, Monika Arenbergerová

Onkologie 2020: 14(Suppl.B): 44-46 | DOI: 10.36290/xon.2020.036  

The treatment of metastatic malignant melanoma includes treatment with anti-PD-1 antibodies (programmed cell death membrane protein), including pembrolizumab. There are different forms of malignant melanoma including acral malignant melanoma (ALM). ALM is associated with poorer prognosis and other biological behavior. There is less evidence of anti-PD-1 antibody efficacy on metastatic ALM than in other forms of melanoma. Our case report focuses on the good respons of pembrolizumab in case of a patient with acral metastatic malignant melanoma.

Immunotherapy: a new hope for patients with a prognostically unfavourable histological type of lung carcinoma

Daniel Doležal, Ondřej Fibigr

Onkologie 2020: 14(Suppl.B): 47-50 | DOI: 10.36290/xon.2020.037  

The article deals with novel treatment options for non-small cell lung carcinoma in an advanced, i.e. metastatic, stage. The case report presents a female patient with an advanced, metastatic pleomorphic carcinoma of the lung, who was treated with pembrolizumab. The results of treatment with this immune checkpoint inhibitor are apparent on the enclosed chest CT scans. Also discussed are the indication criteria for this treatment as well as the possible future and a more widespread use of immunotherapy in oncological settings.

Treatment of young adult pineoblastoma pacient with proton beam therapy and high-dose chemoterapy

Stěpan Vinakurau, Renata Emmerová, Jana Engelová, David Sumerauer, Barbora Ondrová, Jiří Kubeš, Vladimír Vondráček, Alexandra Haas, Tomáš Jirásek, Josef Zámečník, Pavel Buchvald, Zuzana Marečková

Onkologie 2020: 14(Suppl.B): 51-55 | DOI: 10.36290/xon.2020.038  

We present our experience with a treatment of a 35-year old adult female patient with a rare central nervous system tumor pineoblastoma. Postoperative patient was referred to adjuvant pencil beam scanning therapy (PBS) starting with 36 Gy dose of prophylactic craniospinal irradiation followed by a local 23.4 Gy boost to the tumor bed. A total dose of 59.4 Gy was given to the patient along with concurrent temozolomide. After well tolerated proton beam chemoradiotherapy the patient finished 4 cycles of high-dose chemotherapy with peripheral blood hematopoietic stem cell support. At 11 months after proton beam chemoradiotherapy the patient has remained...